← All Bio-path Holdings, INC filings

Bio-path Holdings, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OTC.Pink
BPTH
Bio-path Holdings, INC
10-K: Bio-Path Holdings Reports 2024 Results, Highlights Clinical Progress and Obesity Program
Bio-Path Holdings' 10-K filing summarizes the company's financial results for 2024 and provides updates on its clinical programs, including progress in AML, lymphoma, solid tumors, and its newly initiated obesity program.
OTC.Pink
BPTH
Bio-path Holdings, INC
10-K: Bio-Path Holdings Reports Promising Interim Data in AML Trial, Advances Pipeline
Bio-Path Holdings announces positive interim results from its Phase 2 AML clinical trial and provides updates on its other drug candidates.